Law360 (April 21, 2021, 6:30 PM EDT) — Endo Pharmaceuticals Inc. and Impax Laboratories Inc. told an Illinois federal court that buyers who say they overpaid for Opana ER have to show more than the Federal Trade Commission did when it secured a Fifth Circuit win last week over the alleged delay of generic versions
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
- Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
- Create custom alerts for specific article and case topics and so much more!
TRY LAW360 FREE FOR SEVEN DAYS